Abstract
Mitral regurgitation is the second-most frequent valvular heart disease in Europe and it is associated with high morbidity and mortality. Recognition of MR should encourage the assessment of its etiology, severity, and mechanism in order to determine the best therapeutic approach. Mitral valve surgery constitutes the first-line therapy; however, transcatheter procedures have emerged as an alternative option to treat inoperable and high-risk surgical patients. In patients with suitable anatomy, the transcatheter edge-to-edge mitral leaflet repair is the most frequently applied procedure. In non-reparable patients, transcatheter mitral valve replacement (TMVR) has appeared as a promising intervention. Thus, currently TMVR represents a new treatment option for inoperable or high-risk patients with degenerated or failed bioprosthetic valves (valve-in-valve); failed repairs, (valve-in-ring); inoperable or high-risk patients with native mitral valve anatomy, or those with severe annular calcifications, or valve-in-mitral annular calcification. The patient selection requires multimodality imaging pre-procedural planning to select the best approach and device, study the anatomical landing zone and assess the risk of left ventricular outflow tract obstruction. In the present review, we aimed to highlight the main considerations for TMVR planning from an imaging perspective; before, during, and after TMVR.
Highlights
Mitral regurgitation (MR) is the second-most frequent valvular heart disease encountered in clinical practice in Europe [1], and it is associated with high morbidity and mortality [2]
transcatheter mitral valve replacement (TMVR) for ViR and valve-in-mitral annular calcification (ViMAC) is associated with a higher risk of procedural complications and increased mortality following TMVR
Technical success was 89.1%, and a second valve implant was most frequently needed in ViR followed by ViMAC and ViV
Summary
Mitral regurgitation (MR) is the second-most frequent valvular heart disease encountered in clinical practice in Europe [1], and it is associated with high morbidity and mortality [2]. Recognition of MR should encourage the assessment of its etiology, severity, and mechanism in order to determine the best therapeutic approach [3]. Mitral valve surgery constitutes the first-line therapy for patients with symptomatic severe MR [3]; up to 50% of those affected are not referred for surgery due to high risks [4]. Transcatheter procedures have emerged as an alternative option to treat inoperable and high-risk surgical patients [5]. Represents the most frequently applied percutaneous transcatheter mitral valve procedure.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.